Alterity Therapeutics Ltd (ATHE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has a cash flow conversion efficiency ratio of -0.299x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($42.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alterity Therapeutics Ltd (ATHE) total market value for the company's overall valuation and market capitalisation.
Alterity Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2026)
This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency. See Alterity Therapeutics Ltd debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scorpio Gold Corp
V:SGN
|
-0.081x |
|
Sempio Foods Co
KO:248170
|
0.068x |
|
Groupe LDLC SA
PA:ALLDL
|
-0.164x |
|
Tex Year Industries Inc
TW:4720
|
-0.090x |
|
Allcargo Terminals Ltd
NSE:ATL
|
0.169x |
|
All Cosmos Bio-Tech Holding Corp
TW:4148
|
0.057x |
|
Brimstone Investment Corporation Limited
JSE:BRN
|
0.041x |
|
Algoltek Inc
TWO:6684
|
0.009x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2026)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2026. View today's stock price for Alterity Therapeutics Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $42.73 Million | $-22.03 Million | -0.516x | -90.93% |
| 2025-06-30 | $42.40 Million | $-11.45 Million | -0.270x | +70.44% |
| 2024-06-30 | $13.80 Million | $-12.61 Million | -0.914x | -4.02% |
| 2023-06-30 | $22.81 Million | $-20.04 Million | -0.878x | -152.49% |
| 2022-06-30 | $35.47 Million | $-12.34 Million | -0.348x | +38.84% |
| 2021-06-30 | $30.47 Million | $-17.33 Million | -0.569x | +36.39% |
| 2020-06-30 | $10.55 Million | $-9.43 Million | -0.894x | -6.07% |
| 2019-06-30 | $16.55 Million | $-13.95 Million | -0.843x | -117.06% |
| 2018-06-30 | $16.08 Million | $-6.25 Million | -0.388x | -56.86% |
| 2017-06-30 | $23.69 Million | $-5.87 Million | -0.248x | -4.68% |
| 2016-06-30 | $31.37 Million | $-7.42 Million | -0.237x | +14.91% |
| 2015-06-30 | $39.11 Million | $-10.87 Million | -0.278x | +24.04% |
| 2014-06-30 | $37.69 Million | $-13.79 Million | -0.366x | +35.69% |
| 2013-06-30 | $13.97 Million | $-7.95 Million | -0.569x | +53.26% |
| 2012-06-30 | $5.62 Million | $-6.85 Million | -1.217x | -85.11% |
| 2011-06-30 | $6.93 Million | $-4.56 Million | -0.658x | +26.97% |
| 2010-06-30 | $5.23 Million | $-4.71 Million | -0.900x | +51.72% |
| 2009-06-30 | $3.75 Million | $-6.99 Million | -1.865x | -95.95% |
| 2008-06-30 | $9.89 Million | $-9.41 Million | -0.952x | +41.93% |
| 2007-06-30 | $5.61 Million | $-9.20 Million | -1.639x | -22.82% |
| 2006-06-30 | $8.73 Million | $-11.66 Million | -1.335x | -129.03% |
| 2005-06-30 | $19.51 Million | $-11.37 Million | -0.583x | -321.78% |
| 2004-06-30 | $38.47 Million | $-5.31 Million | -0.138x | +39.11% |
| 2003-06-30 | $15.78 Million | $-3.58 Million | -0.227x | -0.44% |
| 2002-06-30 | $16.68 Million | $-3.77 Million | -0.226x | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more